跳转至内容
Merck
CN

C2430000

克霉唑

European Pharmacopoeia (EP) Reference Standard

别名:

1-[(2-氯苯基)二苯基甲基]-1-H咪唑, 1-(o-氯-α,α-二苯基苄基)咪唑, 1-(o-氯三苯)咪唑

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C22H17ClN2
化学文摘社编号:
分子量:
344.84
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

克霉唑, European Pharmacopoeia (EP) Reference Standard

InChI

1S/C22H17ClN2/c23-21-14-8-7-13-20(21)22(25-16-15-24-17-25,18-9-3-1-4-10-18)19-11-5-2-6-12-19/h1-17H

SMILES string

Clc1ccccc1C(c2ccccc2)(c3ccccc3)n4ccnc4

InChI key

VNFPBHJOKIVQEB-UHFFFAOYSA-N

grade

pharmaceutical primary standard

API family

clotrimazole

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

正在寻找类似产品? 访问 产品对比指南

Application

Clotrimazole EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Other Notes

Sales restrictions may apply.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

pictograms

Exclamation markEnvironment

signalword

Warning

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - Eye Irrit. 2 - Skin Irrit. 2

存储类别

11 - Combustible Solids

wgk

WGK 3


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Sandra Gemma et al.
Journal of medicinal chemistry, 55(15), 6948-6967 (2012-07-13)
Despite recent progress in the fight against malaria, the emergence and spread of drug-resistant parasites remains a serious obstacle to the treatment of infections. We recently reported the development of a novel antimalarial drug that combines the 4-aminoquinoline pharmacophore of
Laura Ravani et al.
International journal of pharmaceutics, 454(2), 695-702 (2013-06-25)
The aim of the present work is to design a new formulation containing clotrimazole (CTZ) loaded into nanostructured lipid carriers (NLC) for the treatment of fungal vaginal infections. In order to obtain formulations with suitable viscosity for mucosal application, NLC
Natalia Mast et al.
Molecular pharmacology, 84(1), 86-94 (2013-04-23)
Although there are currently three generations of antifungal azoles on the market, even the third-generation agents show undesirable interactions with human cytochrome P450 (P450) enzymes. CYP46A1 is a cholesterol-metabolizing P450 in the brain that tightly binds a number of structurally
P W Lücker et al.
Dermatologica, 169 Suppl 1, 51-55 (1984-01-01)
The retention time and the extent of penetration in human skin of [14C] labelled bifonazole in comparison to [14C] labelled clotrimazole were investigated in 8 healthy volunteers. In the course of the investigation the backs of the volunteers were treated
Maria F Sassano et al.
Journal of medicinal chemistry, 56(6), 2406-2414 (2013-02-27)
Colloidal aggregation is the dominant mechanism for artifactual inhibition of soluble proteins, and controls against it are now widely deployed. Conversely, investigating this mechanism for membrane-bound receptors has proven difficult. Here we investigate the activity of four well-characterized aggregators against

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持